Table 3. Comparison between MRSA and non-MRSA regarding antibiotics resistance, device association and patient's outcome.
| MRSA (n=178) |
Non-MRSA (n=72) |
Chi-square value | df value | 95% confidence interval | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| No | % | No | % | Lower bound | Upper bound | ||||
| Oxacillin | 178 | 100 | 3 | 4 | 235.612 | 1 | 0.005 | 0.051 | p<0.001 |
| Gentamicin | 42 | 24 | 7 | 10 | 6.261 | 1 | 1.222 | 6.729 | 0.008 |
| Amikacin | 40 | 22 | 19 | 26 | 0.436 | 1 | 0.430 | 1.520 | 0.307 |
| Clindamycin | 34 | 19 | 8 | 11 | 5.373 | 1 | 1.132 | 5.735 | 0.013 |
| Vancomycin | 39 | 22 | 10 | 14 | 2.093 | 1 | 0.816 | 3.707 | 0.100 |
| Tetracycline | 25 | 14 | 7 | 10 | 0.858 | 1 | 0.625 | 3.683 | 0.240 |
| Erythromycin | 35 | 20 | 11 | 15 | 0.657 | 1 | 0.647 | 2.847 | 0.268 |
| Rifampicin | 63 | 35 | 21 | 29 | 0.891 | 1 | 0.735 | 2.409 | 0.214 |
| Trimethoprim/sulfamethoxazole | 81 | 45 | 25 | 35 | 2.441 | 1 | 0.890 | 2.770 | 0.077 |
| Ciprofloxacin | 34 | 19 | 7 | 10 | 3.289 | 1 | 0.924 | 5.205 | 0.048 |
| Cefoxitin | 178 | 100 | 0 | 0 | 250.000 | 1 | <0.001 | ||
| fnBPA | 44 | 46 | 19 | 26 | 0.076 | 1 | 0.490 | 1.711 | 0.450 |
| PVL | 4 | 2 | 6 | 8 | 4.945 | 1 | 0.069 | 0.925 | 0.036 |
| Gender (male) | 82 | 46 | 41 | 57 | 2.427 | 1 | 0.372 | 1.121 | 0.078 |
| Device | 19.269 | 2 | <0.001 | ||||||
| CLABSI | 28 | 16 | 29 | 40 | |||||
| Ventilator | 36 | 20 | 15 | 20 | |||||
| Urinary catheter | 114 | 64 | 28 | 38 | |||||
| Outcome | 0.003 | ||||||||
| Death | 20 | 11 | 19 | 26 | |||||
| Discharge | 158 | 89 | 53 | 73 | |||||
CLABSI – central line-associated bloodstream infection.